Clinical developments in nanotechnology for cancer therapy.
about
Bioabsorbable polymers in cancer therapy: latest developmentsAn overview of clinical and commercial impact of drug delivery systemsStrategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and marketPolymeric nanoparticles for targeted treatment in oncology: current insightsPotential applications and human biosafety of nanomaterials used in nanomedicineQuantum dot loaded immunomicelles for tumor imaging.Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents.Update on current and potential nanoparticle cancer therapiesEFFECTS OF POLYMERIC NANOPARTICLE SURFACE PROPERTIES ON INTERACTION WITH BRAIN TUMOR ENVIRONMENT.Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries.Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.Cancer cell invasion: treatment and monitoring opportunities in nanomedicine.Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography.Core-Crosslinked Polymeric Micelles: Principles, Preparation, Biomedical Applications and Clinical TranslationIn vitro investigation of silica nanoparticle uptake into human endothelial cells under physiological cyclic stretch.Lipophilic prodrug conjugates allow facile and rapid synthesis of high-loading capacity liposomes without the need for post-assembly purification.Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications.Cancer Cell Internalization of Gold Nanostars Impacts Their Photothermal Efficiency In Vitro and In Vivo: Toward a Plasmonic Thermal Fingerprint in Tumoral Environment.Biological rationale for the design of polymeric anti-cancer nanomedicines.Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence.Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1).Two-Step Delivery: Exploiting the Partition Coefficient Concept to Increase Intratumoral Paclitaxel Concentrations In vivo Using Responsive Nanoparticles.Stimuli-responsive copolymer solution and surface assemblies for biomedical applications.Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis.Evaluation of expansile nanoparticle tumor localization and efficacy in a cancer stem cell-derived model of pancreatic peritoneal carcinomatosis.Design of siRNA Therapeutics from the Molecular ScaleRemote loading of preencapsulated drugs into stealth liposomes.Research progress on siRNA delivery with nonviral carriers.Nanoscale effects on thermodynamics and phase equilibria in oxide systems.Cyclodextrin-containing polymers: versatile platforms of drug delivery materials.Biomedical applications of multifunctional plasmonic nanoparticles.Therapeutic nanoparticles in clinics and under clinical evaluation.Advanced drug delivery nanosystems (aDDnSs): a mini-review.RNA modularity for synthetic biology.Surface modification of nonviral nanocarriers for enhanced gene delivery.In vivo studies of nanostructure-based photosensitizers for photodynamic cancer therapy.Targeted PRINT Hydrogels: The Role of Nanoparticle Size and Ligand Density on Cell Association, Biodistribution, and Tumor Accumulation.Microfluidics-mediated assembly of functional nanoparticles for cancer-related pharmaceutical applications.Delivery of Gemcitabine Prodrugs Employing Mesoporous Silica Nanoparticles.Micellization of antineoplastic agent to significantly upregulate efficacy and security.
P2860
Q26775714-224E0E70-FFF6-4401-8506-53AB0DC39EBBQ27007143-7B4E446C-7AB7-4FB0-A566-3E4E0DE21EF8Q27015050-980F76D6-1A28-4612-8521-1E87EC906EC2Q28087243-413BBB24-B9EE-48CB-8182-3D86F6005F14Q32944368-ADDE8446-6188-40BA-AAA6-303921C5238BQ33721349-9B853278-ECD1-4A93-918F-AEAE0C35759AQ33851179-4FD152B4-CDF8-433B-A43D-EEE2E5AB5C71Q33874239-12CE34A1-C203-475E-A958-5336EAC96836Q34019320-72C78BE6-13FD-473A-A8F0-F78ACE17601AQ34579964-7BFDA2AB-EFE4-4D4D-8E12-16EFE07D6390Q34801630-80A15565-121C-4AA9-82EC-3630EE85D200Q35093966-1DA49BD6-350C-4653-9D71-C5C8AEF83BFCQ35377505-6FF65AE8-AF1D-4CF8-A173-13E9DC7121FFQ35438759-87A11EB1-1DDB-4BF5-AEF7-EF0F3F7F686CQ35533797-5BCDD319-CBDE-4EBF-A2C4-30D0AEEDAF00Q35773072-D6431CD6-D144-4F10-A7E4-27FD06889536Q35897573-2DAF904D-A278-42F4-9B33-F1A33439A507Q35962185-84524839-7527-440E-92CB-555ECD57A93EQ36160333-206A24B9-C516-4FA7-92C6-8012675E43A6Q36354955-96187D43-1D72-428B-9DA0-CB08CD854BF5Q36429985-07E89069-B65F-4C9B-9E8F-FAD04C2F0F83Q36438435-A621DB03-C35A-4F7E-B2DE-9C3CD30C06F2Q36988921-33F106E0-8FE4-4CE3-A2C1-49F3AF4F3836Q37010760-FB7BD967-8D21-4978-9E14-38C7B033CDBFQ37013343-7B0F8391-3878-4776-BDCC-9B900F095080Q37111734-5E65A6CD-D477-495B-88F7-1A2BD12FE3B1Q37587698-47218245-772D-42D5-A9BF-619626F3B757Q37896464-C7218D8E-D40A-4FD1-9219-651CE06AF5EDQ37899840-31915389-40D5-4B3E-BAB5-09D6A622A1B1Q38002033-536C9C62-F1C1-486E-8BAA-46EA95625CBCQ38034178-2E4CE1C9-1A16-47A7-A194-84B64D8BA0E6Q38087986-47305738-D062-4734-886F-FB82FBF033E8Q38153469-3E4ECEBD-3B27-4020-B27E-FE6F5B2E4DF4Q38165944-40A178E4-C906-43AF-B859-78F20C9E6DCAQ38172635-8A74EC80-88EF-4A6D-BC28-239F1D216162Q38244010-CE52CDA7-11C6-4F14-8772-4A35EFCFF697Q38691793-9777086D-860B-41DA-A59D-37E3A35954F2Q38728839-1B0D4E17-EAC5-4876-9A05-FB35BED3090DQ38775652-F464A82F-2A0B-413B-9CB8-8821340AE206Q38941828-DEC8B31A-BD03-4C47-A98D-6EF7F5AFAB5F
P2860
Clinical developments in nanotechnology for cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical developments in nanotechnology for cancer therapy.
@en
Clinical developments in nanotechnology for cancer therapy.
@nl
type
label
Clinical developments in nanotechnology for cancer therapy.
@en
Clinical developments in nanotechnology for cancer therapy.
@nl
prefLabel
Clinical developments in nanotechnology for cancer therapy.
@en
Clinical developments in nanotechnology for cancer therapy.
@nl
P2860
P1476
Clinical developments in nanotechnology for cancer therapy.
@en
P2093
Jeremy D Heidel
Mark E Davis
P2860
P304
P356
10.1007/S11095-010-0178-7
P577
2010-06-12T00:00:00Z